Madrigal Pharmaceuticals
MDGL
379.10
-17.64
-4.45%
Madrigal Pharmaceuticals
US · MDGL
#1355 by market cap
Listed 2016
379.10
-17.64
-4.45%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Rating change
Wells Fargo Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $685Market Newswire · 2026/10/12
-
Rating change
Barclays Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $962Market Newswire · 2026/11/4
-
Citi Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $760Market Newswire · 2026/11/4
-
Rating change
Wolfe Research Upgrades Madrigal Pharmaceuticals(MDGL.US) to Buy Rating, Announces Target Price $605Market Newswire · 2026/8/4
-
H.C. Wainwright Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $620Market Newswire · 2026/11/12
-
Rating change
CCORF Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $612Market Newswire · 2026/10/29
-
Rating change
UBS Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $735Market Newswire · 2026/10/15
-
Rating change
Citi Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Raises Target Price to $760Market Newswire · 2026/11/4
-
Rating change
BofA Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Hold Rating, Cuts Target Price to $533Market Newswire · 2026/10/19
-
Rating change
UBS Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Raises Target Price to $735Market Newswire · 2026/10/14
-
Rating change
Barclays Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Cuts Target Price to $962Market Newswire · 2026/8/4
-
Madrigal Pharmaceuticals(MDGL.US) Director Buys US$35.02 Million in Common StockMarket Newswire · 2026/11/7
-
Rating change
Truist Financial Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Announces Target Price $709Market Newswire · 2026/7/31
-
Rating change
TD Cowen Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $644Market Newswire · 2026/7/31
-
Rating change
Citi Initiates Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Announces Target Price $725Market Newswire · 2026/9/23
-
Rating change
Goldman Sachs Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Raises Target Price to $704Market Newswire · 2026/9/24
-
Rating change
CCORF Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Raises Target Price to $612Market Newswire · 2026/8/12
-
A Quick Look at Today's Ratings for Madrigal Pharmaceuticals(MDGL.US), With a Forecast Between $479 to $743Market Newswire · 2026/11/5
-
Rating change
CCORF Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Raises Target Price to $587Market Newswire · 2026/7/29
-
BofA Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Hold Rating, Maintains Target Price $479Market Newswire · 2026/11/10
-
Rating change
Wells Fargo Initiates Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Announces Target Price $685Market Newswire · 2026/7/27
-
Rating change
Citizens JMP Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Cuts Target Price to $739Market Newswire · 2026/7/17
-
Rating change
BofA Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Hold Rating, Maintains Target Price $542Market Newswire · 2026/7/14
-
Rating change
Barclays Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $962Market Newswire · 2026/9/30
-
Rating change
UBS Initiates Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Announces Target Price $669Market Newswire · 2026/7/22
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Madrigal Pharmaceuticals discussion 0 comments